190 related articles for article (PubMed ID: 28415827)
1. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
Ando K; Shah AK; Sachdev V; Kleinstiver BP; Taylor-Parker J; Welch MM; Hu Y; Salgia R; White FM; Parvin JD; Ozonoff A; Rameh LE; Joung JK; Bharti AK
Oncotarget; 2017 Jul; 8(27):43733-43751. PubMed ID: 28415827
[TBL] [Abstract][Full Text] [Related]
2. Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors.
Ando K; Tohme YH; Srinivasiah A; Taylor-Parker J; Harrington Y; Shah AK; Oki E; Brahmandam M; Bharti AK
J Histochem Cytochem; 2018 Aug; 66(8):549-561. PubMed ID: 29587004
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
4. CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.
Matsuoka H; Ando K; Swayze EJ; Unan EC; Mathew J; Hu Q; Tsuda Y; Nakashima Y; Saeki H; Oki E; Bharti AK; Mori M
PLoS One; 2020; 15(8):e0228002. PubMed ID: 32764831
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
[TBL] [Abstract][Full Text] [Related]
6. Analysis of common gene expression patterns in four human tumor cell lines exposed to camptothecin using cDNA microarray: identification of topoisomerase-mediated DNA damage response pathways.
Guo X; Zhang J; Fu X; Wei Q; Lu Y; Li Y; Yin G; Mao Y; Xie Y; Rui Y; Ying K
Front Biosci; 2006 May; 11():1924-31. PubMed ID: 16368568
[TBL] [Abstract][Full Text] [Related]
7. Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex.
Zhang HF; Tomida A; Koshimizu R; Ogiso Y; Lei S; Tsuruo T
Cancer Res; 2004 Feb; 64(3):1114-21. PubMed ID: 14871846
[TBL] [Abstract][Full Text] [Related]
8. Cellular processing determinants for the activation of damage signals in response to topoisomerase I-linked DNA breakage.
Huang TH; Chen HC; Chou SM; Yang YC; Fan JR; Li TK
Cell Res; 2010 Sep; 20(9):1060-75. PubMed ID: 20603643
[TBL] [Abstract][Full Text] [Related]
9. Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Sharma NK; Kumar A; Kumari A; Tokar EJ; Waalkes MP; Bortner CD; Williams J; Ehrenshaft M; Mason RP; Sinha BK
PLoS One; 2015; 10(11):e0141897. PubMed ID: 26540186
[TBL] [Abstract][Full Text] [Related]
10. WRN counteracts the NHEJ pathway upon camptothecin exposure.
Otsuki M; Seki M; Kawabe Y; Inoue E; Dong YP; Abe T; Kato G; Yoshimura A; Tada S; Enomoto T
Biochem Biophys Res Commun; 2007 Apr; 355(2):477-82. PubMed ID: 17303082
[TBL] [Abstract][Full Text] [Related]
11. pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine.
Sorensen M; Sehested M; Jensen PB
Biochem Pharmacol; 1997 Aug; 54(3):373-80. PubMed ID: 9278096
[TBL] [Abstract][Full Text] [Related]
12. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
Teicher BA
Biochem Pharmacol; 2008 Mar; 75(6):1262-71. PubMed ID: 18061144
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Shamanna RA; Lu H; Croteau DL; Arora A; Agarwal D; Ball G; Aleskandarany MA; Ellis IO; Pommier Y; Madhusudan S; Bohr VA
Oncotarget; 2016 Mar; 7(12):13269-84. PubMed ID: 26959889
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition suppresses DNA-dependent protein kinase activation caused by camptothecin.
Sakasai R; Teraoka H; Tibbetts RS
DNA Repair (Amst); 2010 Jan; 9(1):76-82. PubMed ID: 19959400
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the ubiquitin pathway in decreasing Ku70 levels in response to drug-induced apoptosis.
Gama V; Yoshida T; Gomez JA; Basile DP; Mayo LD; Haas AL; Matsuyama S
Exp Cell Res; 2006 Feb; 312(4):488-99. PubMed ID: 16368436
[TBL] [Abstract][Full Text] [Related]
16. Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction.
Wu Y; Wang KY; Li Z; Liu YP; Izumi H; Uramoto H; Nakayama Y; Ito K; Kohno K
J Exp Clin Cancer Res; 2014 Dec; 33(1):112. PubMed ID: 25539742
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin.
Desai SD; Liu LF; Vazquez-Abad D; D'Arpa P
J Biol Chem; 1997 Sep; 272(39):24159-64. PubMed ID: 9305865
[TBL] [Abstract][Full Text] [Related]
18. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.
Shao RG; Cao CX; Zhang H; Kohn KW; Wold MS; Pommier Y
EMBO J; 1999 Mar; 18(5):1397-406. PubMed ID: 10064605
[TBL] [Abstract][Full Text] [Related]
19. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.
Desai SD; Zhang H; Rodriguez-Bauman A; Yang JM; Wu X; Gounder MK; Rubin EH; Liu LF
Mol Cell Biol; 2003 Apr; 23(7):2341-50. PubMed ID: 12640119
[TBL] [Abstract][Full Text] [Related]
20. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
